Faisal Khurshid

Q: How accurate are Faisal Khurshid's stock ratings?

About 49% of Faisal's ratings were profitable over a one-year hold, with an average return of +37.3% per rating, measured by 13Foresight from historical prices.

Q: How is Faisal ranked?

Faisal Khurshid is ranked #36 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Jefferies

Wall Street Analyst

★★★★★

#36

on 13Foresight · ranked by our own returns

49%

Success Rate

+37.4%

Average Return

28 of 57 calls profitable · +89.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Faisal Khurshid's ratings turned a profit when each position was held for 1 year — averaging +37.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

45 Buy 18 Hold 0 Sell

Faisal's Stock Coverage 39 ratings · 2026-09-29

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
SMMT Summit Therapeutics	Sep 09, 2026	BUY	Strong Buy +89.2% avg upside 29 analysts	$25.00 62.99% Upside	-3.6%	·
ALNY Alnylam Pharma	Sep 08, 2026	HOLD	Strong Buy +24.9% avg upside 51 analysts	$260.00 3.21% Upside	-1.8%	·
RVMD Revolution Medicines	Sep 03, 2026	BUY	Strong Buy -0.3% avg upside 33 analysts	$270.00 32.36% Upside	-2.8%	·
ASND Ascendis Pharma	Aug 31, 2026	BUY	Strong Buy +23.9% avg upside 26 analysts	$330.00 43.78% Upside	-14.2%	·
IMTX Immatics	Aug 25, 2026	BUY	Strong Buy +115.2% avg upside 15 analysts	$17.00 102.52% Upside	-9.4%	·
EYPT EyePoint Pharmaceuticals	Aug 17, 2026	BUY	Strong Buy +588.5% avg upside 21 analysts	$8.00 142.44% Upside	-25.7%	·
INSM Insmed	Aug 06, 2026	BUY	Strong Buy +47.3% avg upside 37 analysts	$175.00 48.20% Upside	-11.3%	·
GLUE Monte Rosa Therapeutics	Jul 31, 2026	BUY	Strong Buy +96.9% avg upside 15 analysts	$25.00 115.27% Upside	-28.7%	·
ONC BeOne Medicines	Jul 12, 2026	BUY	Strong Buy -0.7% avg upside 28 analysts	$380.00 4.16% Upside	+18.7%	·
ABVX Abivax SA Sponsored ADR	Jul 01, 2026	BUY	Strong Buy +38.7% avg upside 16 analysts	$158.00 65.07% Upside	-26.9%	·
VRDN Viridian Therapeutics	Jun 30, 2026	BUY	Strong Buy +71.4% avg upside 32 analysts	$30.00 47.80% Upside	+11.4%	·
VSTM Verastem	Jun 23, 2026	BUY	Strong Buy +100.3% avg upside 24 analysts	$8.00 7.34% Upside	+83.9%	·
PTCT PTC Therapeutics	May 27, 2026	BUY	Buy +24.6% avg upside 29 analysts	$85.00 30.97% Upside	-11.3%	·
SNDX Syndax Pharmaceuticals	May 01, 2026	BUY	Strong Buy +96.2% avg upside 27 analysts	$37.00 108.36% Upside	-4.8%	·
FDMT 4D Molecular Therapeutics	Mar 30, 2026	BUY	Strong Buy +136.6% avg upside 16 analysts	$21.00 47.53% Upside	+68.8%	·
ANIP ANI Pharmaceuticals	Mar 25, 2026	BUY	Strong Buy +38.1% avg upside 12 analysts	$120.00 64.23% Upside	+1.0%	·
COGT Cogent Biosciences	Mar 16, 2026	BUY	Strong Buy +21.2% avg upside 26 analysts	$55.00 74.91% Upside	-11.6%	·
KYMR Kymera Therapeutics	Mar 15, 2026	BUY	Strong Buy -1.1% avg upside 37 analysts	$110.00 1.41% Downside	+39.3%	·
INCY Incyte	Mar 15, 2026	HOLD	Buy -12.1% avg upside 48 analysts	$94.00 24.18% Downside	+33.2%	·
IMCR Immunocore Holdings	Mar 15, 2026	HOLD	Strong Buy +110.3% avg upside 22 analysts	$33.00 8.10% Upside	+0.9%	·
DSGN Design Therapeutics	Mar 15, 2026	BUY	Strong Buy +47.3% avg upside 9 analysts	$15.00 23.51% Upside	+11.4%	·
CTNM Contineum Therapeutics, Inc. Class A	Dec 15, 2025	BUY	Strong Buy +63.9% avg upside 9 analysts	$21.00 60.60% Upside	+8.5%	·
RYTM Rhythm Pharmaceuticals	Dec 15, 2025	BUY	Strong Buy +26.5% avg upside 22 analysts	$142.00 47.04% Upside	-12.3%	·
ABCL AbCellera Biologics	Nov 07, 2025	HOLD	Strong Buy +15.9% avg upside 16 analysts	$4.00 69.41% Downside	+223.5%	·
NRIX Nurix Therapeutics	Oct 23, 2025	HOLD	Strong Buy +37.5% avg upside 28 analysts	$12.00 47.86% Downside	+127.6%	·
LKFT Lakefront Biotherapeutics	Oct 22, 2025	BUY	Buy +245.4% avg upside 25 analysts	$40.00 34.63% Upside	-7.8%	·
MNKD MannKind	Oct 10, 2025	BUY	Buy +112.2% avg upside 22 analysts	$9.00 169.77% Upside	-32.6%	·
PRTCY PureTech Health	Sep 30, 2025	BUY	Strong Buy +231.3% avg upside 3 analysts	—	-16.8%	·
ZURA Zura Bio	Sep 30, 2025	BUY	Strong Buy +285.6% avg upside 13 analysts	—	+3.9%	·
ATYR aTyr Pharma	Sep 30, 2025	HOLD	Buy +2648.5% avg upside 17 analysts	—	-57.7%	·
TRVI Trevi Therapeutics	Sep 29, 2025	BUY	Strong Buy +65.8% avg upside 18 analysts	—	+59.8%	·
IMUX Immunic	Sep 25, 2025	BUY	Strong Buy +307.8% avg upside 22 analysts	—	+4.1%	·
PTGX Protagonist Therapeutics	Sep 18, 2025	BUY	Strong Buy -15.6% avg upside 19 analysts	—	+130.1%	·
SYRE Spyre Therapeutics	Sep 11, 2025	BUY	Strong Buy +9.6% avg upside 23 analysts	—	+459.3%	·
STTK Shattuck Labs	Aug 18, 2025	BUY	Strong Buy +236.7% avg upside 16 analysts	$2.00 67.39% Downside	+630.4%	·
GERN Geron	Aug 12, 2025	BUY	Strong Buy +243.2% avg upside 19 analysts	$3.00 142.87% Upside	+16.3%	·
PLRX Pliant Therapeutics	Aug 07, 2025	HOLD	Buy +1955.4% avg upside 21 analysts	$2.00 84.42% Upside	-37.5%	·
IRWD Ironwood Pharma	Aug 07, 2025	HOLD	Hold +188.2% avg upside 23 analysts	$1.00 75.51% Downside	+390.9%	·
FR:SAN Sanofi	Jul 28, 2025	BUY	Strong Buy +35.3% avg upside 30 analysts	—	-1.7%	·

🔒 34 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Faisal Khurshid — Frequently Asked Questions

How accurate are Faisal Khurshid's stock ratings?

Based on the calls 13Foresight could measure, about 49% of Faisal's ratings were profitable over a one-year hold, with an average return of +37.3% per rating, or +89.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Faisal ranked on 13Foresight?

Faisal Khurshid is currently ranked #36 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Faisal cover?

Faisal most recently has ratings on SMMT, ALNY, RVMD, ASND, IMTX, EYPT, INSM, GLUE, ONC, ABVX, VRDN, VSTM and 27 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Faisal Khurshid

Rating Distribution

Welcome to 13Foresight!